Page 3 - Regor Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Regor therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Regor Therapeutics Today - Breaking & Trending Today

Eli Lilly pens $1.5B biobucks pact with China's Regor for metabolic disease work

Eli Lilly is making a $1.5 billion biobucks bet on Chinese biotech Regor Therapeutics to seek out, develop and hopefully sell new therapies for metabolic disorders. ....

Hong Kong , Republic Of China , Taiwan General , Eli Lilly , Ruth Gimeno , Regor Therapeutics , Computer Accelerated Rational Discovery , Licensing Deals ,

Lilly deepens research ties in China with biotech deal

BioPharma ....

Hong Kong , Eli Lilly , Dive Brief , Regor Therapeutics , Lilly Asia Ventures ,

General Atlantic, IDG lead $100m fourth round for Chinese biotech firm Biotheus

General Atlantic, IDG lead $100m fourth round for Chinese biotech firm Biotheus
Source: National Cancer Institute/Unsplash
March 4, 2021
Biotheus, a Chinese biotech firm focusing on the treatment of malignant tumours and autoimmune diseases, has secured over $100 million in its fourth funding round co-led by growth equity investor General Atlantic and Beijing-based investment firm IDG Capital.
New investors in the round include Chinese private equity (PE) firm Kunlun Capital, CITIC’s asset management firm CPE, and Shenzhen-based PE Cowin Capital, Biotheus said in a statement on Wednesday.
Returning investors such as healthcare-focused investment companies HighLight Capital and Shiyu Capital, Chinese fund manager New Alliance Capital, and Huajin Investment participated in the deal. ....

United States , Liu Xiaolin , Yisheng Biopharma , Valliance Capital , General Atlantic , Kunlun Capital , Highlight Capital , Shiyu Capital , New Alliance Capital , Huajin Investment , Regor Therapeutics , Lilly Asia Ventures , Investigational New Drug , Series Pre A , ஒன்றுபட்டது மாநிலங்களில் , கூட்டணி மூலதனம் , ஜநரல் அட்லாண்டிக் , முன்னிலைப்படுத்த மூலதனம் , புதியது கூட்டணி மூலதனம் , லில்லி ஆசியா முயற்சிகள் , தொடர் பிரே ,

Regor Therapeutics Announces Completion of $90 Million Series B Financing

Regor Therapeutics Announces Completion of $90 Million Series B Financing
News provided by
Share this article
Share this article
SHANGHAI, Feb. 18, 2021 /PRNewswire/ Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, announces the successful completion of $90 million Series B financing.
Founded in July of 2018 by a group of veteran drug hunters with extensive research and executive leadership experiences at top multinational pharmaceutical companies, Regor aims to establish world-class innovation capabilities and is committed to delivering clinically differentiated, best- and first-in-class drugs to serve patients globally. By leveraging CARD, Computer Accelerated Rational Discovery, a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion, including from ....

United States , Hong Kong , Xiayang Qiu , Yi Shi , Randy Lin , Regor Therapeutics Group , Tamasek Holdings , Qilu Pharmaceutical Group , Computer Accelerated Rational Discovery , Lilly Asia Ventures , Loyal Valley Capital , Planting Capital , Vertex Ventures , Regor Therapeutics , Regor Therapeutic , Lilly Asia , Loyal Valley , Asia Ventures , Valley Capital , Tik Tok , Pop Mart , Influential Private Equity Firms , Drug Investor , Ting Capital , Vertex Ventures China , Ventures China ,

Lilly Asia Ventures leads $90m Series B in clinical-stage biotech firm Regor

Lilly Asia Ventures leads $90m Series B in clinical-stage biotech firm Regor
February 19, 2021
Regor Therapeutics, a clinical-stage biotech company with operations in China and the US, has secured $90 million in a Series B round of financing led by the biomedical venture capital (VC) firm Lilly Asia Ventures (LAV).
The new round saw participation from investors including China-focused private equity (PE) firm Loyal Valley Capital (LVC); cross-border, pharmaceutical-focused PE Lanting Capital (LVC); TF Capital, which primarily invests in early-stage life sciences startups; and Vertex Ventures China.
Chinese drug maker Qilu Pharmaceutical Group had backed Regor’s Series A round.
Founded in July 2018, Regor specialises in the discovery and delivery of clinically differentiated, best- and first-in-class drugs for patients globally to treat cancer, immune disorders, and metabolic diseases. ....

Qiu Xiayang , Exchange Commission , Qilu Pharmaceutical Group , Los Angeles County Employees Retirement Association , Fund Vi Opportunities , Regor Therapeutics , Lilly Asia Ventures , Loyal Valley Capital , Vertex Ventures , Computer Accelerated Rational Discovery , San Francisco Employee Retirement System , பரிமாற்றம் தரகு , லாஸ் ஏஞ்சல்ஸ் கவுண்டி ஊழியர்கள் ஓய்வு சங்கம் , நிதி வி வாய்ப்புகள் , லில்லி ஆசியா முயற்சிகள் , விசுவாசமான பள்ளத்தாக்கு மூலதனம் , வெர்டெக்ஸ் முயற்சிகள் , கணினி முடுக்கப்பட்ட ர்யாஶநல் கண்டுபிடிப்பு , சான் பிரான்சிஸ்கோ ஊழியர் ஓய்வு அமைப்பு ,